CGEM
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Cullinan Therapeutics, Inc. (CGEM) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | B+ (3.8) | C+ (2.8) | C+ (2.5) | C+ (2.6) | B- (2.9) |
| 2026-11-04 | C+ (2.5) | B+ (3.8) | C+ (2.8) | B- (3.0) | C+ (2.7) | B- (2.9) |
| 2026-10-28 | C+ (2.5) | B+ (3.7) | C+ (2.8) | B- (2.9) | C+ (2.7) | B- (2.9) |
| 2026-10-21 | C+ (2.5) | B+ (3.7) | C+ (2.8) | B (3.3) | C+ (2.6) | B- (3.0) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe